Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept studyPeter Connick, Siddharthan Chandran, Madhan Kolappan et al.|The Lancet Neurology|2012Cited by 606
The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessmentsPeter Connick, Siddharthan Chandran, Madhan Kolappan et al.|Trials|2011Cited by 119
Molecular MRD is strongly prognostic in patients with <i>NPM1</i>-mutated AML receiving venetoclax-based nonintensive therapyJad Othman, Richard Dillon, Mariam Amer et al.|Blood|2023Cited by 65
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> MutationsNigel H. Russell, Shankara Paneesha, Charlotte S. Wilhelm-Benartzi et al.|Journal of Clinical Oncology|2024Cited by 40